Bipolar 3 is not an official psychiatric diagnosis. It’s a proposed subtype within the “bipolar spectrum” concept, referring specifically to people who experience hypomania (a milder form of mania) only when taking antidepressant medication. The term was introduced by psychiatrist Hagop Akiskal as part of a broader argument that bipolar disorder exists on a continuum, with several subtypes beyond the two recognized in standard diagnostic manuals.
If you searched this term, you may have encountered it on social media, in a psychology article, or from someone describing their own experience. Here’s what the concept actually means, how it differs from the official bipolar diagnoses, and why it matters for people taking antidepressants.
Where the Term Comes From
The current psychiatric diagnostic system recognizes three bipolar-related conditions: bipolar I, bipolar II, and cyclothymic disorder. That’s it. There is no “bipolar 3” in the DSM-5-TR, the manual clinicians use to diagnose mental health conditions in the United States, or in the ICD system used internationally.
The concept of bipolar 3 comes from Akiskal’s bipolar spectrum model, which proposed several additional subtypes to capture people whose mood patterns don’t fit neatly into the existing categories. In this framework, type III specifically describes antidepressant-induced hypomania: a person who has depression, takes an antidepressant, and then develops a hypomanic episode as a result. Under current diagnostic rules, that antidepressant-triggered episode doesn’t qualify someone for a bipolar II diagnosis because the hypomania didn’t occur spontaneously.
Akiskal also proposed other subtypes, including depression combined with a strong family history of bipolar disorder, and a concept called “hyperthymia,” which describes people who live in a constant state of mild hypomania as a baseline personality trait rather than in distinct episodes.
What Antidepressant-Induced Hypomania Looks Like
The core feature of the bipolar 3 concept is hypomania that shows up only during antidepressant treatment. Hypomania itself involves a noticeable shift toward elevated or irritable mood, increased energy, reduced need for sleep, racing thoughts, and sometimes impulsive behavior. It’s less severe than full mania (you can still function, and you don’t lose touch with reality), but it’s a clear departure from your normal state.
In a validation study comparing people with antidepressant-associated hypomania to those with spontaneous hypomania (bipolar II), about 10.5% of the sample experienced hypomania only during antidepressant use. These individuals tended to have underlying depressive temperamental instability, meaning their baseline mood leaned toward depression and emotional reactivity. Their hypomanic episodes also appeared later in life compared to people with bipolar II, and by definition, these episodes occurred only during pharmacotherapy.
For the person experiencing it, this can be confusing. You started an antidepressant for depression, and now you feel unusually energized, talkative, or impulsive. You might feel great at first, sleeping less but powering through your days, only to realize the shift is destabilizing. Some people cycle into a worse depressive episode after the hypomanic phase passes.
Why It’s Not an Official Diagnosis
The main reason bipolar 3 hasn’t entered the diagnostic manuals is a fundamental question: does antidepressant-induced hypomania reveal an underlying bipolar condition, or is it simply a side effect of the medication? The distinction matters because it changes how clinicians think about long-term treatment.
If the hypomania signals a hidden bipolar vulnerability, these patients may need mood stabilizers rather than antidepressants. If it’s purely a drug reaction, stopping or switching the antidepressant should resolve the problem without reclassifying the person’s entire diagnosis. Researchers have described antidepressant-associated hypomania as something that “might provisionally be categorized as bipolar III,” acknowledging the pattern is real while stopping short of calling it a settled diagnosis.
The broader bipolar spectrum concept does have population-level support. Surveys across multiple countries suggest that between 4% and 6% of adults may experience subthreshold bipolar presentations, conditions that share features with bipolar disorder but don’t meet full diagnostic criteria. Lifetime prevalence for these soft-spectrum presentations varies widely by country, from as low as 0.1% in some populations to around 2% in others.
How It Differs From Bipolar I, II, and Cyclothymia
Understanding where bipolar 3 sits requires knowing what the official categories look like.
- Bipolar I involves at least one full manic episode, which is severe enough to impair daily functioning or require hospitalization. Depressive episodes are common but not required for diagnosis.
- Bipolar II involves at least one hypomanic episode and at least one major depressive episode, with no history of full mania. The hypomania occurs on its own, not triggered by medication.
- Cyclothymic disorder involves chronic fluctuation between mild depressive symptoms and mild hypomanic symptoms for at least two years, with symptoms present at least half the time and no symptom-free stretch longer than two months.
The bipolar 3 concept describes someone who looks like they have plain depression, potentially for years, until an antidepressant unmasks a hypomanic response. They don’t have the spontaneous mood cycling of bipolar II or the chronic low-grade fluctuations of cyclothymia. Their hypomania is specifically tied to pharmacological treatment.
The Role of Family History
Genetics plays a significant role in bipolar disorder broadly. The heritability rate is estimated at 60% to 80%, and first-degree relatives of someone with bipolar disorder face roughly a tenfold increase in risk compared to the general population. Siblings of people with bipolar disorder have a 5% to 10% prevalence rate, while identical twins show concordance rates above 50%.
No single gene causes bipolar disorder. Multiple gene locations across several chromosomes (including the 4th, 12th, and 18th) have been implicated, and the inheritance pattern doesn’t follow simple dominant or recessive rules. Transmission risk from the mother’s side and father’s side appears to be similar.
This genetic backdrop is relevant to the bipolar 3 concept because Akiskal’s spectrum model suggests that a strong family history of bipolar disorder, even in someone who has only experienced depression, may indicate they sit somewhere on the bipolar continuum. If that person then develops hypomania on an antidepressant, the family history adds weight to interpreting the episode as something more than a simple medication side effect.
What This Means for Treatment
If you’ve experienced a mood shift while taking an antidepressant, whether that’s unusual energy, decreased sleep without fatigue, racing thoughts, or uncharacteristic impulsivity, this is important information for your clinician. Even though bipolar 3 isn’t a formal diagnosis, the pattern it describes is clinically meaningful.
In practice, clinicians who recognize this pattern often consider switching from a standard antidepressant to a mood stabilizer, or adding one alongside the antidepressant. The goal is to manage the depression without repeatedly triggering hypomanic episodes that destabilize mood further. The specific approach depends on the severity of the reaction, your history of depressive episodes, and whether you have other risk factors like a family history of bipolar disorder.
People with this pattern tend to have a more complicated treatment path than those with straightforward depression. Antidepressants that work well for unipolar depression can be destabilizing for someone with an underlying bipolar vulnerability, creating a frustrating cycle of medication trials. Recognizing the pattern early, and communicating any mood changes to your provider clearly, can shorten that process considerably.